Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions
Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions作者机构：Kitzen Pharmaceutical Consulting Collegeville PA USA Temple University School of Medicine Philadelphia PA USA NEMA Research Inc. Naples FL USA Neumentum Inc. Palo Alto CA USA University of Arizona College of Pharmacy Tucson AZ USA Temple University School of Pharmacy Philadelphia PA USA
出 版 物：《Pharmacology & Pharmacy》 (药理与制药（英文）)
年 卷 期：2018年第9卷第9期
页 面：357-381页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Crisaborole Apremilast Phosphodiesterase PDE4 Inflammation Cytokines Interleukins cAMP
摘 要：Two selective phosphodiesterase-4 (PDE4) inhibitors—viz., crisaborole (Eucrisa®, Pfizer) and apremilast (Otezla®, Celgene)—have recently received approval by the United States Food and Drug Administration for the treatment of related but different dermatologic skin conditions (viz., atopic dermatitis and plaque psoriasis, respectively). The purpose of this review is to summarize the underlying biochemistry and pathophysiology associated with these dermatologic conditions, review the chemistry, pharmacology and safety of each of these products, and present preclinical and clinical evidence that may help explain why these two PDE4 inhibitors offer new treatment options for these skin conditions.
维普期刊数据库